BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 30371224)

  • 21. Predictors of hyporesponsiveness to erythropoiesis-stimulating agents in hemodialysis patients.
    Kalantar-Zadeh K; Lee GH; Miller JE; Streja E; Jing J; Robertson JA; Kovesdy CP
    Am J Kidney Dis; 2009 May; 53(5):823-34. PubMed ID: 19339087
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness impact of iron dextran on hemodialysis patients' use of epoetin alfa and blood.
    Driver PS
    Am J Health Syst Pharm; 1998 Dec; 55(24 Suppl 4):S12-6. PubMed ID: 9872688
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chapter 8 Haemoglobin, ferritin and erythropoietin amongst UK adult dialysis patients in 2010: national and centre-specific analyses.
    Webb L; Gilg J; Wilkie M
    Nephron Clin Pract; 2012; 120 Suppl 1():c145-74. PubMed ID: 22964566
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of facility-level hemoglobin concentration on dialysis patient risk of transfusion.
    Collins AJ; Monda KL; Molony JT; Li S; Gilbertson DT; Bradbury BD
    Am J Kidney Dis; 2014 Jun; 63(6):997-1006. PubMed ID: 24315770
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Achievement of renal anemia KDIGO targets by two different clinical strategies - a European hemodialysis multicenter analysis.
    Drozdz M; Weigert A; Silva F; Frazão J; Alsuwaida A; Krishnan M; Kleophas W; Brzosko S; Johansson FK; Jacobson SH
    BMC Nephrol; 2019 Jan; 20(1):5. PubMed ID: 30616548
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Greater potency of darbepoetin-α than erythropoietin in suppression of serum hepcidin-25 and utilization of iron for erythropoiesis in hemodialysis patients.
    Shoji S; Inaba M; Tomosugi N; Okuno S; Ichii M; Yamakawa T; Kurihara S
    Eur J Haematol; 2013 Mar; 90(3):237-44. PubMed ID: 23281632
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Evaluation of serum iron as a predictor of a hemoglobin response to injectable iron treatment in chronic hemodialysis patients].
    Grèze C; Garrouste C; Pereira B; Hadj-Abdelkader M; Heng AÉ; Aniort J
    Nephrol Ther; 2022 Dec; 18(7):634-642. PubMed ID: 36216731
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Performance of a Predictive Model for Long-Term Hemoglobin Response to Darbepoetin and Iron Administration in a Large Cohort of Hemodialysis Patients.
    Barbieri C; Bolzoni E; Mari F; Cattinelli I; Bellocchio F; Martin JD; Amato C; Stopper A; Gatti E; Macdougall IC; Stuard S; Canaud B
    PLoS One; 2016; 11(3):e0148938. PubMed ID: 26939055
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Australian haemodialysis patients on intravenous epoetin alfa or intravenous darbepoetin alfa: how do they compare?
    Pussell BA; Walker R;
    Nephrology (Carlton); 2007 Apr; 12(2):126-9. PubMed ID: 17371333
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study.
    Coyne DW; Kapoian T; Suki W; Singh AK; Moran JE; Dahl NV; Rizkala AR;
    J Am Soc Nephrol; 2007 Mar; 18(3):975-84. PubMed ID: 17267740
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reticulocyte hemoglobin content predicts functional iron deficiency in hemodialysis patients receiving rHuEPO.
    Mittman N; Sreedhara R; Mushnick R; Chattopadhyay J; Zelmanovic D; Vaseghi M; Avram MM
    Am J Kidney Dis; 1997 Dec; 30(6):912-22. PubMed ID: 9398141
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term maintenance of hemoglobin levels in hemodialysis patients treated with bi-weekly epoetin beta pegol switched from darbepoetin alfa: a single-center, 12-month observational study in Japan.
    Kawai T; Kusano Y; Yamada K; Ueda C; Kawai A; Masaki T
    J Artif Organs; 2019 Jun; 22(2):146-153. PubMed ID: 30426250
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Low versus high dose erythropoiesis-stimulating agents in hemodialysis patients with anemia: A randomized clinical trial.
    Saglimbene V; Palmer SC; Craig JC; Ruospo M; Nicolucci A; Tonelli M; Johnson D; Lucisano G; Williams G; Valentini M; D'Alonzo D; Pellegrini F; Strippoli P; Salomone M; Santoro A; Maffei S; Hegbrant J; Tognoni G; Strippoli GF;
    PLoS One; 2017; 12(3):e0172735. PubMed ID: 28249030
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of additional iron doses on hepcidin-25 level in hemodialysis patients without evident iron deficiency.
    Brătescu LO; Bârsan L; Gârneaţă L; Stanciu A; Lipan M; Stancu SH; Mircescu G
    Int Urol Nephrol; 2014 May; 46(5):1005-12. PubMed ID: 24800994
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of erythropoiesis-stimulating agents among chemotherapy patients with hemoglobin exceeding 12 grams per deciliter.
    Nordstrom BL; Luo W; Fraeman K; Whyte JL; Nordyke RJ
    J Manag Care Pharm; 2008; 14(9):858-69. PubMed ID: 19006442
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low levels of serum ferritin lead to adequate hemoglobin levels and good survival in hemodialysis patients.
    Ogawa C; Tsuchiya K; Kanda F; Maeda T
    Am J Nephrol; 2014; 40(6):561-70. PubMed ID: 25592750
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Iron, inflammation, dialysis adequacy, nutritional status, and hyperparathyroidism modify erythropoietic response.
    Gaweda AE; Goldsmith LJ; Brier ME; Aronoff GR
    Clin J Am Soc Nephrol; 2010 Apr; 5(4):576-81. PubMed ID: 20110344
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recombinant human erythropoietin independence in chronic hemodialysis patients: clinical features, iron homeostasis and erythropoiesis.
    Kuo CC; Lee CT; Chuang CH; Su Y; Chen JB
    Clin Nephrol; 2005 Feb; 63(2):92-7. PubMed ID: 15730050
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictors of the response to treatment in anemic hemodialysis patients with high serum ferritin and low transferrin saturation.
    Singh AK; Coyne DW; Shapiro W; Rizkala AR;
    Kidney Int; 2007 Jun; 71(11):1163-71. PubMed ID: 17396118
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Longer-term outcomes of darbepoetin alfa versus epoetin alfa in patients with ESRD initiating hemodialysis: a quasi-experimental cohort study.
    Winkelmayer WC; Chang TI; Mitani AA; Wilhelm-Leen ER; Ding V; Chertow GM; Brookhart MA; Goldstein BA
    Am J Kidney Dis; 2015 Jul; 66(1):106-13. PubMed ID: 25943715
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.